Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial

Fig. 3

Patients who achieved 56-day transfusion independence. *The proportion of patients who were transfusion-dependent at baseline and achieved transfusion independence for at least 56 consecutive days after receiving at least one dose of olutasidenib plus azacitidine combination therapy. Other responders are patients with CRi, MLFS, or PR. Non-responders are patients in response assessment categories other than CR, CRh, CRi, PR, and MLFS. CR, complete remission; CRh, CR with partial hematologic recovery; CRi, CR with incomplete recover; MLFS, morphologic leukemia-free state; PR, partial remission

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us